Two experimental studies by Garcia-Quiroz et al. demonstrated the capacity of astemizole, an old second-generation H1 antihistamine, to inhibit breast cancer tumour growth in vitro28 and in vivo29 by targeting Eag1, a potassium ion channel involved in tumour progression. The gene discussed is KCNH1; the disease is breast carcinoma.